Primary Progressive Multiple Sclerosis (PPMS) Treatment Market Report 2026

The primary progressive multiple sclerosis (ppms) treatment market size has grown rapidly in recent years. It will grow from $1.16 billion in 2025 to $1.31 billion in 2026 at a compound annual growth rate (CAGR) of 13.7%. The growth in the historic period can be attributed to limited treatment options for ppms, reliance on corticosteroids for symptom management, low awareness of ppms among patients, underdeveloped hospital pharmacy infrastructure, slow adoption of immunosuppressants.

The primary progressive multiple sclerosis (ppms) treatment market size is expected to see rapid growth in the next few years. It will grow to $2.18 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to introduction of targeted monoclonal antibodies, increasing r&d in neurodegenerative disorders, expansion of hospital and online pharmacy networks, rising regulatory approvals for novel therapeutics, growth in patient awareness and early diagnosis programs. Major trends in the forecast period include rising adoption of monoclonal antibodies for ppms, increased focus on symptom management and quality of life, growth in intravenous drug administration preference, expansion of hospital and specialty pharmacy channels, development of novel therapeutics and combination therapies.

The increasing demand for effective treatments is anticipated to drive the growth of the primary progressive multiple sclerosis (PPMS) treatment market in the coming years. Effective treatments are medical interventions that alleviate symptoms, improve patient outcomes, or manage disease progression. The rising demand for effective treatments is mainly driven by the growing prevalence of chronic and complex conditions that require long-term care and advanced therapeutic solutions to enhance quality of life. In PPMS, effective treatments help slow disease progression by reducing inflammation and preserving neurological function, thereby limiting disability accumulation, improving long-term outcomes, and enabling patients to maintain greater independence in daily activities. For instance, in January 2024, according to the American Society of Gene & Cell Therapy, a US-based organization dedicated to gene and cell therapy, the number of gene therapies in Phase III clinical trials reached 33 in 2023, reflecting a 10% increase compared to 2022 and marking the first quarterly rise since the third quarter of 2022. Therefore, the growing demand for effective treatments is driving the growth of the primary progressive multiple sclerosis (PPMS) treatment market.

Major companies operating in the primary progressive multiple sclerosis (PPMS) treatment market are emphasizing the development of innovative therapies, such as monoclonal antibody drugs, to improve multiple sclerosis management. Monoclonal antibody drugs help treat multiple sclerosis by selectively targeting immune cells or proteins responsible for inflammation and nerve damage, thereby reducing disease activity and slowing symptom progression. For example, in February 2024, Roche Pharma India, an India-based pharmaceutical company, introduced Ocrevus (ocrelizumab), a monoclonal antibody therapy, for the treatment of multiple sclerosis in India. Ocrevus is recognized as the first and only approved disease-modifying therapy for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS) in the country. The drug targets CD20-positive B cells involved in the abnormal immune response associated with MS and is administered as a twice-yearly intravenous infusion lasting approximately two hours, offering patients a convenient and effective treatment option.

In March 2024, Viatris Inc., a US-based healthcare company focused on expanding access to medicines, partnered with Mapi Pharma Ltd. to support the development and commercialization of GA Depot 40 mg for the treatment of multiple sclerosis. Through this collaboration, Viatris assists in advancing the regulatory and commercial pathway for GA Depot, a long-acting injectable formulation designed to improve treatment adherence and address unmet needs in multiple sclerosis care. Mapi Pharma Ltd. is an Israel-based pharmaceutical company specializing in depot and sustained-release drug delivery technologies for central nervous system disorders, including multiple sclerosis.

Major companies operating in the primary progressive multiple sclerosis (ppms) treatment market are F. Hoffmann-La Roche Ltd., Biogen Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Acorda Therapeutics Inc., Apitope International N.V., Atara Biotherapeutics Inc., Kyverna Therapeutics Inc., Clene Inc., Mapi Pharma Ltd., Abata Therapeutics Inc., MediciNova Inc., MedDay Pharmaceuticals SAS, AB Science S.A., Immunic AG, BrainStorm Cell Therapeutics Inc., TG Therapeutics Inc., EMD Serono Inc. (Merck KGaA), Mitsubishi Tanabe Pharma Corporation, Sanofi Genzyme, Alexion Pharmaceuticals (AstraZeneca Rare Disease), Viela Bio (Horizon Therapeutics), Receptos (Celgene/Bristol-Myers Squibb), Forward Pharma A/S, InnoCare Pharma, NervGen Pharma Corp., Priovant Therapeutics, Tiziana Life Sciences, Reata Pharmaceuticals, Biohaven Pharmaceutical Holding Company, Anokion SA.

North America was the largest region in the primary progressive multiple sclerosis (PPMS) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary progressive multiple sclerosis (ppms) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the primary progressive multiple sclerosis (ppms) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the ppms treatment market by increasing the cost of imported active pharmaceutical ingredients (apis) and biologics used in monoclonal antibodies and immunosuppressants. Segments such as intravenous therapies and specialty drugs are particularly impacted, with regions like Europe and Asia-Pacific experiencing higher import duties. This has led to increased treatment costs and supply chain realignments. Positively, tariffs have encouraged local manufacturing, regional production investments, and the development of cost-efficient biosimilars.

The primary progressive multiple sclerosis (ppms) treatment market research report is one of a series of new reports that provides primary progressive multiple sclerosis (ppms) treatment market statistics, including primary progressive multiple sclerosis (ppms) treatment industry global market size, regional shares, competitors with a primary progressive multiple sclerosis (ppms) treatment market share, detailed primary progressive multiple sclerosis (ppms) treatment market segments, market trends and opportunities, and any further data you may need to thrive in the primary progressive multiple sclerosis (ppms) treatment industry. This primary progressive multiple sclerosis (ppms) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Primary progressive multiple sclerosis (PPMS) treatment involves medical and therapeutic strategies designed to manage and slow the progression of PPMS, a form of multiple sclerosis marked by a steady decline in neurological function from symptom onset without clear relapses or periods of remission. These treatments aim to modify disease activity, relieve symptoms, preserve mobility, and enhance overall quality of life.

The main drug types used in treating primary progressive multiple sclerosis (PPMS) include monoclonal antibodies, immunosuppressants, corticosteroids, and other drug categories. Monoclonal antibodies (mAbs) are laboratory-developed proteins engineered to selectively bind to specific antigens on diseased cells for therapeutic or diagnostic use. These medications are administered through various routes, including oral, intravenous, and other methods, and are distributed through hospital pharmacies, retail pharmacies, online pharmacies, and additional distribution channels.

The primary progressive multiple sclerosis (PPMS) treatment market consists of sales of ocrelizumab (ocrevus), mitoxantrone, baclofen, modafinil and oxybutynin. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.